PIoneering The Next Generation Of Targeted Psychoactive Medications

Artboard – 1_2x.png
Strip – 1_2x.png

3 Primary Breakthroughs For The Treatment Of Mental Health Issues.

Discovered an efficient, patent-pending bacterial biosynthesis process for tryptamine production.

1_2x.png
2_2x.png

Demonstrated the entourage effect of certain tryptamines in a laboratory-controlled environment.

3_2x.png

Developing a portfolio of tryptamine-derived, psychedelically inspired molecules.

Strip_2x.png

Leaders In The Development of Next Generation Psychoactive Pharmaceuticals

Mock up_2x.png

Paradigm Shift For Treating Mental Illness and Neurological Disorders

PsyBio Therapeutics is developing biosynthetic psychoactive compounds which offer a new paradigm of treatment to reverse the course of mental health issues.

Left side graphic_2x.png
Strip_2x.png

PsyBio Therapeutics is creating a portfolio of unique, scientifically developed, psychoactive compounds as potential therapeutic agents for mental and neurologic health issues 

PsyBio’s Objective Is to Develop Ground-Breaking Patient Treatments Based Upon Psychedelic Agents

Research & Development Partners

Miami University, Oxford, OH

Manufacturing

Curia Global
Biose Industrie
Berkeley Lab

Analyst Coverage

Maxim Group
Noble Capital Markets

Pills_2x.png
Bullet_2x.png
Bullet_2x.png
Bullet_2x.png

Psybio Has World Class Team Of Leaders and Experts

Management is key to a successful biotechnology company in obtaining FDA approval for its leading therapeutic candidates.

Experienced CEO with over 25 years in the Biotech Industry.
Chief Medical Officer with Expanded Clinical Trial. 
Excellent Board of Directors.

Send Us a Message

 

Investor Inquiries